Dr. Mark S. Box, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 523
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Missouri, Columbia School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
MO license R1J62 · KS license 04-26764
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- St Lukes Hospital of Kansas City Kansas City, MO
- Golden Valley Memorial Hospital Clinton, MO
- St Joseph Medical Center Kansas City, MO
- Bates County Memorial Hospital Butler, MO
Medical groups
- Signature Medical Group of Kc PA (27 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 523
- Services billed
- 177,005
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 63,767 | 15 |
| Injection, golimumab, 1 mg, for intravenous use | 33,703 | 42 |
| Injection, infliximab, excludes biosimilar, 10 mg | 10,151 | 28 |
| Injection, denosumab, 1 mg | 9,900 | 100 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,140 | 456 |
| Administration of chemotherapy into vein, 1 hour or less | 695 | 105 |
| Established patient office or other outpatient visit, 20-29 minutes | 691 | 217 |
| Infusion, normal saline solution, 250 cc | 676 | 112 |
| Injection of drug or substance under skin or into muscle | 316 | 118 |
| Administration of chemotherapy into vein, each additional hour | 306 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Kansas City, MO | 654 |
| Prednisone Other prescribers in Kansas City, MO | 471 |
| Tramadol Hcl Other prescribers in Kansas City, MO | 384 |
| Methotrexate (methotrexate sodium) Other prescribers in Kansas City, MO | 381 |
| Hydroxychloroquine Sulfate Other prescribers in Kansas City, MO | 355 |
| Meloxicam Other prescribers in Kansas City, MO | 353 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Kansas City, MO | 344 |
| Alprazolam Other prescribers in Kansas City, MO | 327 |
| Gabapentin Other prescribers in Kansas City, MO | 299 |
| Oxycodone Hcl Other prescribers in Kansas City, MO | 291 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 302 payments worth $34,647 in total to this clinician.
| AbbVie Inc. | $9,029 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $7,545 |
| E.r. Squibb & Sons, L.l.c. | $6,999 |
| GlaxoSmithKline, LLC. | $4,201 |
| Amgen Inc. | $3,423 |
| Pfizer Inc. | $483 |
| UCB, Inc. | $437 |
| Janssen Biotech, Inc. | $434 |
| Compensation for services other than consulting (speaking, faculty) | $17,800 |
|---|---|
| Consulting Fee | $7,938 |
| Food and Beverage | $6,283 |
| Travel and Lodging | $2,427 |
| Education | $199 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Sep 15, 2025 | Consulting Fee | $5,738 |
| AstraZeneca Pharmaceuticals LP Jul 8, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $3,700 |
| AbbVie Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,550 |
| Amgen Inc. Dec 23, 2025 | Consulting Fee KRYSTEXXA · Inflammation/Rare Disease | $2,200 |
| AstraZeneca Pharmaceuticals LP Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $1,850 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| GlaxoSmithKline, LLC. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| AbbVie Inc. Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,275 |
| AbbVie Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,275 |
| AbbVie Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,275 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Dec 23, 2025 | Consulting Fee KRYSTEXXA · Inflammation/Rare Disease | $2,200 |
| GlaxoSmithKline, LLC. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| E.r. Squibb & Sons, L.l.c. Oct 7, 2025 | Travel and Lodging travel to DENVER, CO | $90.70 |
| E.r. Squibb & Sons, L.l.c. Sep 15, 2025 | Consulting Fee | $5,738 |
| AstraZeneca Pharmaceuticals LP Sep 7, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $100 |
| E.r. Squibb & Sons, L.l.c. Sep 6, 2025 | Travel and Lodging travel to Denver, CO | $392 |
| E.r. Squibb & Sons, L.l.c. Sep 5, 2025 | Travel and Lodging travel to Denver, CO | $311 |
| GlaxoSmithKline, LLC. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $650 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,275 |
| Mallinckrodt Hospital Products Inc. Jul 30, 2025 | Education ACTHAR · IMMUNOLOGY · in-kind Company’s descriptionRelevant medical textbook or clinical reprint | $99.99 |
| AstraZeneca Pharmaceuticals LP Jul 8, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $3,700 |
| AbbVie Inc. Jul 7, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $44.10 |
| AbbVie Inc. Jul 7, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $32.00 |
| AbbVie Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,550 |
| AstraZeneca Pharmaceuticals LP Jun 26, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to Springfield, MO · in-kind Company’s descriptionSpeaker Expenses | $941 |
| AbbVie Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,275 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $238 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $188 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $150 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $40.00 |
| Janssen Biotech, Inc. Jun 4, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| AbbVie Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,275 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| AstraZeneca Pharmaceuticals LP Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $1,850 |
| GlaxoSmithKline, LLC. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $650 |
| AbbVie Inc. Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,275 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $31,289 in research payments for these studies, mostly to the institutions running them.
- Phase 3B4 randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor tnf inhibitor in subjects with rheumatoid arthritis
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.